Ipsen S.A. Sponsored ADR (IPSEY)
OTC PINK OTC PINK Primary Summary
Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
Ipsen S.A. (OTCPK:IPSEY) Q1 2025 Results Conference Call April 16, 2025 8:00 AM ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Conference Call Participants Shan Hama - Jefferies John Priestner - JPMorgan Florent Cespedes - Bernstein Xian Deng - UBS Simon Baker - Redburn Atlantic Manos Mastorakis - Deutsche Bank Alistair Campbell - RBC Laura Hindley - Morgan Stanley Operator Hello, and welcome to Ipsen's Conference Call and Webcast for the First Quarter 2025 Results. I'll now hand you over to David Loew, Ipsen's CEO.
Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript
Ipsen S.A. (OTCPK:IPSEY) Q4 2024 Earnings Call February 13, 2025 7:00 AM ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Christelle Huguet - Head, R&D Conference Call Participants Xian Deng - UBS John Priestner - JPMorgan Simon Baker - Redburn Atlantic Sachin Jain - Bank of America Florent Cespedes - Bernstein Shan Hama - Jefferies Richard Parkes - BNP Paribas Laura Hindley - Morgan Stanley Operator Hello and welcome to Ipsen's Conference Call and Webcast on Full Year 2024 Results. I'll now hand you over to David Loew, Ipsen's CEO.
Ipsen S.A. Sponsored ADR (IPSEY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Ipsen S.A. Sponsored ADR ever had a stock split?
Ipsen S.A. Sponsored ADR Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. David Loew CEO | OTC PINK Exchange | 462629205 CUSIP |
| FR Country | 5,358 Employees | 9 Jun 2025 Last Dividend | - Last Split | - IPO Date |
Overview
Ipsen S.A. is a globally operating biopharmaceutical company, with a foundation that traces back to 1929. Situated in Boulogne-Billancourt, France, Ipsen is at the forefront of developing innovative drugs across three primary areas: oncology, neuroscience, and rare diseases. Through extensive research and development, Ipsen is committed to providing cutting-edge treatments and solutions aimed at addressing some of the most challenging conditions faced in the medical world today.
Products and Services
- Cabometyx + Atezolizumab - Currently in phase III clinical trial for the treatment of second-line metastatic castration-resistant prostate cancer. This combination therapy represents Ipsen's dedication to advancing cancer treatment.
- Lenalidomide and Rituximab, and Taverik - In phase III for the treatment of second-line follicular lymphoma, highlighting the company's focus on innovative oncology solutions.
- Bylvay - A phase III drug for the treatment of biliary atresia. Ipsen's work in rare diseases showcases their commitment to addressing less common, yet impactful, conditions.
- Dysport - Undergoing phase III clinical trial for chronic and episodic migraine treatment. This demonstrates Ipsen's involvement in the neuroscience field, tackling debilitating neurological conditions.
- Fidrisertib - In phase II clinical trial for treating fibrodysplasia ossificans progressiva. Ipsen is exploring treatments for extremely rare and challenging diseases.
- Elafibranor - Also in phase II, aimed at treating primary sclerosing cholangitis. Through such developments, Ipsen is making strides in the realm of rare diseases.
- Neurotoxin Products (IPN60250; IPN10200; IPN60210) - These are in various stages of clinical trials, with efforts focusing on longer-acting neurotoxin aesthetics and therapeutics, showcasing Ipsen's commitment to innovative solutions in both cosmetic and therapeutic areas.
- IPN60260 - In phase I clinical trial for the treatment of viral cholestatic disease, representing another of Ipsen's ventures into rare disease treatment.
- Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik - These oncology products further validate Ipsen's strong presence and continued investment in cancer treatment.
- Dysport and other Neuroscience Products - This includes treatments not only for migraines but also for other neurological conditions, affirming Ipsen's commitment to neuroscience.
- Bylvay, NutropinAq, Increlex, and Sohonos - As part of Ipsen's rare diseases portfolio, these products address various rare conditions, furthering the company's dedication to improving the lives of patients with rare diseases.
Contact Information
